CLINICAL BREAST CANCER, cilt.22, sa.3, 2022 (SCI-Expanded)
The aim of this study was to evaluate the effects of complex decongestive therapy (CDT) in patients with breast cancer-related lymphedema (BCRL), in regard to volume reduction, functional status and quality-of-life (QoL). CDT in combined manner performed daily for 3 weeks, can greatly reduce the volume as well as improve the disability and impaired QoL, especially when performed earlier in patients with BCRL.